Alliances
The spike began after the six-person company announced it had entered into a multi-year services agreement with Merck KGaA.
Tiny ITUS believes it is on track to develop a CAR-T treatment for solid tumors.
Aspen Pharmacare Holdings, a South African generic drug company, plans to establish partnerships to build its China drug portfolio, according to management.
In the latest joint effort, Lee’s Pharm will pair its PD-L1 candidate with icaritin.
Award of approximately USD 37 million will support clinical work required for product approval.
A number of biopharma companies are making strides in developing non-opioid pain killers or opioids that are more difficult to abuse.
Peptidream has scored another billion dollar-plus agreement to develop peptide-based therapies aimed at the treatment multiple disease targets.
Under the deal, CUE will leverage its CUE Biologics platform to develop biologics engineered to affect specific T-cell subpopulations to treat autoimmune diseases.
Ionis Pharma and Janssen have strengthened their alliance with a second deal for gastrointestinal drugs.
PRESS RELEASES